GLP-1 medications such as Ozempic have reshaped treatment for Type 2 diabetes. These drugs can help patients manage blood sugar, lower cardiovascular risk, and, in many cases, lose a substantial amount of weight. But researchers are still trying to determine whether those physical health improvements also extend into other parts of life, such as mental health, relationships, and employment.
A new National Bureau of Economic Research working paper from University of Chicago Harris School of Public Policy economist Robert Kaestner and coauthor Cuiping Schiman examined that question. Among adults with diabetes, the researchers found little evidence that using GLP-1 medications produced measurable changes in mental health, self-rated health, employment, or marital status. "We know these drugs improve health outcomes, and there's been a great deal of research documenting those benefits," said Kaestner, a research professor.
"What hadn't really been examined was whether those improvements extended into other parts of people's lives." The issue is becoming increasingly important as insurers and government programs consider whether to broaden access to GLP-1 medications. Their medical benefits are already well documented, but it is less clear whether the drugs also produce social or economic gains that could add to the argument for wider coverage. To investigate, Kaestner and Schiman studied more than 10 years of data from the nationally representative Medical Expenditure Panel Survey.
Their analysis focused on adults with diabetes between 2012 and 2023. Instead of only comparing people who used GLP-1 medications with those who did not, the researchers followed the same individuals over time. This allowed them to look at whether a person's circumstances changed after starting treatment.
They examined several indicators of well-being, including depression symptoms, psychological distress, self-rated health, employment, and marital status. At first, GLP-1 users appeared to differ from non-users in some areas, including employment and marriage. However, those differences mostly disappeared when the researchers looked at changes within the same individuals over time.
That pattern suggests the original gaps may have reflected differences between the types of people who used GLP-1 drugs and those who did not, rather than effects caused by the medications themselves. The results were similar whether the researchers looked at people after roughly one year of GLP-1 use or followed them over a longer, two-year period. In both cases, they found little evidence that taking the medications led to meaningful changes in the broader life outcomes they measured.
Extract — continue reading at the source.
